Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.

CONCLUSION: As an inhibitor of CD26/DPP4, Vildagliptin could be a promising therapeutic candidate for idiopathic pulmonary fibrosis. PMID: 32731178 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32731178?dopt=Abstract

Source: International Immunopharmacology - July 26, 2020 Category: Allergy & Immunology Authors: Liu Y, Qi Y Tags: Int Immunopharmacol Source Type: research

More News: Allergy & Immunology | Science | Study